Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

14

Revenue 2017

Lilly

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Lilly's 2013 sales performance.

Lilly

Eli Lilly/AbCellera’s COVID-19 variant-targeting antibody enters clinical trials

Eli Lilly/AbCellera’s COVID-19 variant-targeting antibody enters clinical trials

An antibody targeting variants of COVID-19, developed as part of a collaboration between Eli Lilly and Canadian biotech company AbCellera, has entered clinical trials. ... The need for antibodies that combat variants of concern is growing substantially,

The new reality of building a corporate brand in pharma

The new reality of building a corporate brand in pharma But, if you asked the same people who manufacture those medicines, far fewer people would have been able to answer Pfizer or Lilly respectively.

Lilly cuts 2021 guidance to reflect ‘lower expected revenue’ from COVID-19 antibody sales

Lilly cuts 2021 guidance to reflect ‘lower expected revenue’ from COVID-19 antibody sales In the first quarter, Lilly reported a net income of $1.355bn, down from the $1.457bn reported in the same period last year. ... In Q1, the total revenue for Lilly’s COVID-19 antibodies was $650.6m in the US and $159.5m elsewhere.

Lilly asks to revoke emergency authorisation for bamlanivimab monotherapy in the US

Lilly asks to revoke emergency authorisation for bamlanivimab monotherapy in the US Following this, Lilly advanced the further development of bamlanivimab plus another of its neutralising mAbs – etesevimab – to be administered together. ... However, Lilly said that it is not requesting the withdrawal of emergency authorisation for

Lilly’s RET inhibitor Retevmo shows early promise in new cancer types

Lilly’s RET inhibitor Retevmo shows early promise in new cancer types According to Lilly, responses were ongoing in 73% of responding patients in the study. ... Hyman said that Lilly will discuss the new data in the broad range of cancer types with regulatory authorities this year.

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Spirit

We find the soul in the science, the humanity in the data, harnessing the power of creativity to deliver medical...

Latest intelligence

How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
Deep 6 AI: the smart software breathing new life into clinical trials
Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....
COVID-proof: How Teams are Creating Launch Intensity thru Adversity
Now that the game has changed, how are marketers shifting their launch behaviour? We've identified 5 common observations from effective teams....